Prostate Cancer | Specialty

Likelihood for Cardiovascular Events After ADT

May 21st 2018

Androgens and Cardiovascular Events

May 21st 2018

Cardio-Oncology in Prostate Cancer

May 21st 2018

Reducing the Risk for Cardiovascular Events: PRONOUNCE

May 21st 2018

Significance of GnRH Antagonists in Prostate Cancer

May 21st 2018

Challenges Associated with ADT in Prostate Cancer

May 21st 2018

Burden of Cardiovascular Disease in Prostate Cancer

May 21st 2018

ADT as Treatment in Metastatic Prostate Cancer

May 21st 2018

Task Force Changes Stance on Value of PSA Test

May 21st 2018

The US Preventive Services Task Force has concluded that there is a small mortality benefit associated with prostate-specific antigen-based prostate cancer screening for men aged 55 to 69 years, a departure from earlier guidance.

Study Findings Complicate the Paradigm for Hormone-Sensitive Prostate Cancer

May 21st 2018

Data from recent trials in metastatic hormone-sensitive prostate cancer have demonstrated the heterogeneous nature of prostate cancer and its subtypes, highlighting the importance of a more cautious approach in choosing therapies for patients.

Dr. Choyke on Combining Imaging Techniques in Prostate Cancer

May 14th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the combination of imaging techniques in prostate cancer.

Focusing on Risk Stratification in Prostate Cancer

May 14th 2018

The National Comprehensive Cancer Network has overhauled its guidelines for managing prostate cancer with a greater emphasis on risk stratification for molecular testing and therapy choices.

Expert Discusses Radiation Techniques, Genomic Testing in Prostate Cancer

May 11th 2018

James B. Yu, MD, discusses techniques with radiation therapy, potential roadblocks, and the importance of genomic testing in treating patients with prostate cancer.

Novel Radionuclide Treatment Shows Promise in mCRPC

May 11th 2018

Radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 nearly doubled median PSA progression-free survival in men with progressive metastatic castrate-resistant prostate cancer compared with previous results with radium-223.

Dr. Mark on the Use of Degarelix in Men With Prostate Cancer

May 8th 2018

James Ryan Mark, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the use of degarelix (Firmagon) in the treatment of men with prostate cancer.

Dr. Godwin on Ongoing Clinical Trials for Men With Prostate Cancer

May 8th 2018

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses ongoing trials for men with prostate cancer.

Dr. Trabulsi Defines Locally Advanced Prostate Cancer

May 7th 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

The Case for Platinum Therapy in Prostate Cancer

May 2nd 2018

The arsenal of therapeutic options for men with castration-resistant prostate cancer has steadily grown as ongoing research uncovers more about prostate cancer biology and resistance mechanisms.

Dr. Choyke on Advancements in Imaging for Prostate Cancer

April 30th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses advances in imaging for prostate cancer.

Dr. Den Discusses the Future of Prostate Cancer Research

April 25th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.